Initial clinical observations suggest high level of T cells reprogramming and CAR-T expansion at the starting dose without lymphodepletion At 28 days after a single dose of ESO-T01, no cancer cells ...
EDINBURGH, Scotland, Jan. 17, 2025 /PRNewswire/ -- Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results